NRBO (NeuroBo Pharmaceuticals) Other Stockholders Equity : $-0.00 Mil (As of Jun. 2024)

View and export this data going back to 2016. Start your Free Trial

What is NeuroBo Pharmaceuticals Other Stockholders Equity?

NeuroBo Pharmaceuticals's Other Stockholders Equity for the quarter that ended in Jun. 2024 was $-0.00 Mil.

NeuroBo Pharmaceuticals's quarterly Other Stockholders Equity declined from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($0.00 Mil) and declined from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($-0.00 Mil).

NeuroBo Pharmaceuticals's annual Other Stockholders Equity increased from Dec. 2021 ($-0.00 Mil) to Dec. 2022 ($0.00 Mil) and increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

NeuroBo Pharmaceuticals Other Stockholders Equity Historical Data

The historical data trend for NeuroBo Pharmaceuticals's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroBo Pharmaceuticals Other Stockholders Equity Chart

NeuroBo Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Stockholders Equity

Get a 7-Day Free Trial

NeuroBo Pharmaceuticals Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Other Stockholders Equity	Get a 7-Day Free Trial															-	-	-	-	-

NeuroBo Pharmaceuticals Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

NeuroBo Pharmaceuticals Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of NeuroBo Pharmaceuticals's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroBo Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroBo Pharmaceuticals Inc (NAS:NRBO) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

545 Concord Avenue, Suite 210, Cambridge, MA, USA, 02138

Website

https://www.neurobopharma.com

NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

Executives

Dong-a St Co., Ltd	10 percent owner	64, CHEONHO-DAERO, DONGDAEMUN-GU, SEOUL M5 02587
James Patrick Tursi	director	106 ASHLEY COURT, MOORESTOWN NJ 08057
Marshall H Woodworth	officer: Acting Chief Financial Officer	C/O NEUROBO PHARMACEUTICALS, INC., 545 CONCORD AVENUE, SUITE 210, CAMBRIDGE MA 02138
Mark A Glickman	director	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Joseph Hooker	officer: Interim CEO and President	C/O NEUROBO PHARMACEUTICALS, INC., 200 BERKELEY ST, OFFICE 19TH FLOOR, BOSTON MA 02116
Goldman Sachs Group Inc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
E&healthcare Investment Fund Ii	10 percent owner	16TH FLOOR, YEOKSAM I-TOWER, 326, TEHERAN-RO, GANGNAM-GU, SEOUL M5 06211
E&investment, Inc.	10 percent owner	16TH FLOOR, YEOKSAM I-TOWER, B/D 326, TEHERAN-RO, GANGNAM-GU, SEOUL M5 00000
Hyung Heon Kim	director	C/O DONG-A ST & DONG-A SOCIO GROUP, 64 CHEONHO DAERO, DONGDAEMUN-GU, SEOUL M5 00000
Na Yeon Kim	director, 10 percent owner	C/O NEUROBO PHARMACEUTICALS, INC., 177 HUNTINGTON AVENUE, SUITE 1700, BOSTON MA 02115
Andrew I Koven	director	3 COLUMBUS CIRCLE, SUITE 1710, C/O ARALEZ PHARMACEUTICALS INC., NEW YORK NY 10019
Richard Kang	director	9451 SUNNYFIELD COURT, POTOMAC MD 20854
D Gordon Strickland	director	C/O AMPEX CORPORATION, 1228 DOUGLAS AVENUE, REDWOOD CITY CA 94063
Ben Gil Price	officer: CEO and President	8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896